IN8bio Email Format

Biotechnology ResearchNew York, United States11-50 Employees

IN8bio is a clinical-stage biotechnology company based in New York, New York, focused on developing gamma-delta T cell therapies for cancer. It advances discovery, development, and potential commercialization through its DeltEx platform, which integrates gamma-delta T cell biology with genetic engineering and specialized manufacturing capabilities. The company pursues diverse therapeutic approaches, including allogeneic, autologous, and genetically modified gamma-delta T cell strategies designed to identify and eradicate tumor cells.

In June 2026, IN8bio announced a Nature Communications publication detailing advances in gamma-delta T cell engineering and combination therapies, illustrating ongoing research activity. Operating within the biotechnology and cancer immunotherapy space, the company maintains a clinical-stage focus and communicates progress through scientific outlets while based in New York, New York.

Sign up for free to view info

Company overview Employee directory